A Neanderthal OAS1 isoform protects individuals of European ancestry against COVID-19 susceptibility and severity.
2',5'-Oligoadenylate Synthetase
/ genetics
Aged
Aged, 80 and over
Animals
COVID-19
/ etiology
Case-Control Studies
Female
Genetic Predisposition to Disease
Humans
Interleukin-10 Receptor beta Subunit
/ genetics
Male
Mendelian Randomization Analysis
Middle Aged
Neanderthals
Protein Isoforms
/ physiology
Quantitative Trait Loci
SARS-CoV-2
Severity of Illness Index
White People
Journal
Nature medicine
ISSN: 1546-170X
Titre abrégé: Nat Med
Pays: United States
ID NLM: 9502015
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
11
10
2020
accepted:
05
02
2021
pubmed:
27
2
2021
medline:
29
4
2021
entrez:
26
2
2021
Statut:
ppublish
Résumé
To identify circulating proteins influencing Coronavirus Disease 2019 (COVID-19) susceptibility and severity, we undertook a two-sample Mendelian randomization (MR) study, rapidly scanning hundreds of circulating proteins while reducing bias due to reverse causation and confounding. In up to 14,134 cases and 1.2 million controls, we found that an s.d. increase in OAS1 levels was associated with reduced COVID-19 death or ventilation (odds ratio (OR) = 0.54, P = 7 × 10
Identifiants
pubmed: 33633408
doi: 10.1038/s41591-021-01281-1
pii: 10.1038/s41591-021-01281-1
doi:
Substances chimiques
IL10RB protein, human
0
Interleukin-10 Receptor beta Subunit
0
Protein Isoforms
0
OAS1 protein, human
EC 2.7.7.-
2',5'-Oligoadenylate Synthetase
EC 2.7.7.84
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
659-667Subventions
Organisme : Medical Research Council
ID : MC_UU_00006/1
Pays : United Kingdom
Références
Johns Hopkins University of Medicine. Coronavirus Resource Center. https://coronavirus.jhu.edu/ (2020).
Weinreich, D. M. et al. REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19. N. Engl. J. Med. 384, 238–251 (2020).
Horby, P. et al. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa2021436 (2020).
Sterne, J. A. C. et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis. JAMA 324, 1330–1341 (2020).
Beigel, J. H., Tomashek, K. M. & Dodd, L. E. Remdesivir for the treatment of Covid-19—preliminary report. N. Engl. J. Med. 383, 994 (2020).
Cavalcanti, A. B. et al. Hydroxychloroquine with or without azithromycin in mild-to-moderate Covid-19. N. Engl. J. Med. 383, 2041–2052 (2020).
Nelson, M. R. et al. The support of human genetic evidence for approved drug indications. Nat. Genet. 47, 856–860 (2015).
doi: 10.1038/ng.3314
Cook, D. et al. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat. Rev. Drug Discov. 13, 419–431 (2014).
doi: 10.1038/nrd4309
Zheng, J. et al. Phenome-wide Mendelian randomization mapping the influence of the plasma proteome on complex diseases. Nat. Genet. 52, 1122–1131 (2020).
Filbin, M. R. et al. Plasma proteomics reveals tissue-specific cell death and mediators of cell–cell interactions in severe COVID-19 patients. Preprint at bioRxiv https://doi.org/10.1101/2020.11.02.365536 (2020).
Davey Smith, G., Ebrahim, S., Smith, G. D. & Ebrahim, S. ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int. J. Epidemiol. 32, 1–22 (2003).
doi: 10.1093/ije/dyg070
Giambartolomei, C. et al. Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. PLoS Genet. 10, e1004383 (2014).
doi: 10.1371/journal.pgen.1004383
Lawlor, D. A., Tilling, K. & Smith, G. D. Triangulation in aetiological epidemiology. Int. J. Epidemiol. 45, 1866–1886 (2016).
COVID-19 Host Genetics Initiative. The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur. J. Hum. Genet. 28, 715–718 (2020).
Sun, B. B. et al. Genomic atlas of the human plasma proteome. Nature 558, 73–79 (2018).
doi: 10.1038/s41586-018-0175-2
Emilsson, V. et al. Co-regulatory networks of human serum proteins link genetics to disease. Science 361, 769–773 (2018).
Pietzner, M. et al. Genetic architecture of host proteins involved in SARS-CoV-2 infection. Nat. Commun. 11, 6397 (2020).
doi: 10.1038/s41467-020-19996-z
Folkersen, L. et al. Mapping of 79 loci for 83 plasma protein biomarkers in cardiovascular disease. PLoS Genet. 13, e1006706 (2017).
doi: 10.1371/journal.pgen.1006706
Yao, C. et al. Genome-wide mapping of plasma protein QTLs identifies putatively causal genes and pathways for cardiovascular disease. Nat. Commun. 9, 3268 (2018).
doi: 10.1038/s41467-018-05512-x
Suhre, K. et al. Connecting genetic risk to disease end points through the human blood plasma proteome. Nat. Commun. 8, 14357 (2017).
doi: 10.1038/ncomms14357
COVID-19 Host Genetics Initiative. https://www.covid19hg.org/results/ (2021).
Pairo-Castineira, E. et al. Genetic mechanisms of critical illness in Covid-19. Nature https://doi.org/10.1038/s41586-020-03065-y (2020).
Staley, J. R. et al. PhenoScanner: a database of human genotype–phenotype associations. Bioinformatics 32, 3207–3209 (2016).
doi: 10.1093/bioinformatics/btw373
Prüfer, K. et al. A high-coverage Neandertal genome from Vindija Cave in Croatia. Science 358, 655–658 (2017).
Meyer, M. et al. A high-coverage genome sequence from an archaic Denisovan individual. Science 338, 222–226 (2012).
Sams, A. J. et al. Adaptively introgressed Neandertal haplotype at the OAS locus functionally impacts innate immune responses in humans. Genome Biol. 17, 246 (2016).
Li, H. et al. Identification of a Sjögren’s syndrome susceptibility locus at OAS1 that influences isoform switching, protein expression, and responsiveness to type I interferons. PLoS Genet. 13, e1006820 (2017).
doi: 10.1371/journal.pgen.1006820
Liu, X. et al. A functional variant in the OAS1 gene is associated with Sjögren’s syndrome complicated with HBV infection. Sci. Rep. 7, 17571 (2017).
Li, Y. I. et al. Annotation-free quantification of RNA splicing using LeafCutter. Nat. Genet. 50, 151–158 (2018).
Aguet, F. et al. The GTEx Consortium atlas of genetic regulatory effects across human tissues. Science 369, 1318–1330 (2020).
Aguet, F. et al. Genetic effects on gene expression across human tissues. Nature 550, 204–213 (2017).
doi: 10.1038/nature24277
Hornung, V., Hartmann, R., Ablasser, A. & Hopfner, K. P. OAS proteins and cGAS: unifying concepts in sensing and responding to cytosolic nucleic acids. Nat. Rev. Immunol. 14, 521–528 (2014).
Kristiansen, H. et al. Extracellular 2′–5′ oligoadenylate synthetase stimulates RNase L-independent antiviral activity: a novel mechanism of virus-induced innate immunity. J. Virol. 84, 11898–11904 (2010).
doi: 10.1128/JVI.01003-10
Zeberg, H. & Pääbo, S. A genomic region associated with protection against severe COVID-19 is inherited from Neandertals. Proc. Natl Acad. Sci. USA 118, e2026309118 (2021).
doi: 10.1073/pnas.2026309118
Mendez, F. L., Watkins, J. C. & Hammer, M. F. Neandertal origin of genetic variation at the cluster of OAS immunity genes. Mol. Biol. Evol. 30, 798–801 (2013).
doi: 10.1093/molbev/mst004
Bonnevie-Nielsen, V. et al. Variation in antiviral 2′–5′-oligoadenylate synthetase (2′5′AS) enzyme activity is controlled by a single-nucleotide polymorphism at a splice-acceptor site in the OAS1 gene. Am. J. Hum. Genet. 76, 623–633 (2005).
Carey, C. M. et al. Recurrent loss-of-function mutations reveal costs to OAS1 antiviral activity in primates. Cell Host Microbe 25, 336–343 (2019).
Zeberg, H. & Pääbo, S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. Nature 587, 610–612 (2020).
Schneider, W. M., Chevillotte, M. D. & Rice, C. M. Interferon-stimulated genes: a complex web of host defenses. Annu. Rev. Immunol. 32, 513–545 (2014).
doi: 10.1146/annurev-immunol-032713-120231
Min, J.-Y. & Krug, R. M. The primary function of RNA binding by the influenza A virus NS1 protein in infected cells: inhibiting the 2′–5′ oligo (A) synthetase/RNase L pathway. Proc. Natl Acad. Sci. USA 103, 7100–7105 (2006).
doi: 10.1073/pnas.0602184103
Hu, B. et al. Cellular responses to HSV-1 infection are linked to specific types of alterations in the host transcriptome. Sci. Rep. 6, 28075 (2016).
doi: 10.1038/srep28075
Lim, J. K. et al. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog. 5, e1000321 (2009).
doi: 10.1371/journal.ppat.1000321
Simon-Loriere, E. et al. High anti-dengue virus activity of the OAS gene family is associated with increased severity of dengue. J. Infect. Dis. 212, 2011–2020 (2015).
doi: 10.1093/infdis/jiv321
Hamano, E. et al. Polymorphisms of interferon-inducible genes OAS-1 and MxA associated with SARS in the Vietnamese population. Biochem. Biophys. Res. Commun. 329, 1234–1239 (2005).
doi: 10.1016/j.bbrc.2005.02.101
Cheng, G. et al. Pharmacologic activation of the innate immune system to prevent respiratory viral infections. Am. J. Respir. Cell Mol. Biol. 45, 480–488 (2011).
doi: 10.1165/rcmb.2010-0288OC
Harari, D., Orr, I., Rotkopf, R., Baranzini, S. E. & Schreiber, G. A robust type I interferon gene signature from blood RNA defines quantitative but not qualitative differences between three major IFNβ drugs in the treatment of multiple sclerosis. Hum. Mol. Genet. 24, 3192–3205 (2014).
doi: 10.1093/hmg/ddv071
Lin, F. & Young, H. A. Interferons: success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 25, 369–376 (2014).
Arabi, Y. M. et al. Interferon beta-1b and lopinavir–ritonavir for Middle East respiratory syndrome. N. Engl. J. Med. 383, 1645–1656 (2020).
WHO Solidarity Trial Consortium. Repurposed antiviral drugs for COVID-19—interim WHO SOLIDARITY trial results. N. Engl. J. Med. 384, 497–511 (2021).
Monk, P. D. et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respir. Med. 9, 196–206 (2020).
Wood, E. R. et al. The role of phosphodiesterase 12 (PDE12) as a negative regulator of the innate immune response and the discovery of antiviral inhibitors. J. Biol. Chem. 290, 19681–19696 (2015).
doi: 10.1074/jbc.M115.653113
Silverman, R. H. & Weiss, S. R. Viral phosphodiesterases that antagonize double-stranded RNA signaling to RNase L by degrading 2-5A. J. Interferon Cytokine Res. 34, 455–463 (2014).
Zhao, L. et al. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe 11, 607–616 (2012).
Zhang, R. et al. Homologous 2′,5′-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity. Proc. Natl Acad. Sci. USA 110, 13114–13119 (2013).
Li, Y. et al. SARS-CoV-2 induces double-stranded RNA-mediated innate immune responses in respiratory epithelial derived cells and cardiomyocytes. Preprint at bioRxiv https://doi.org/10.1101/2020.09.24.312553 (2020).
Burgess, S., Davies, N. M. & Thompson, S. G. Bias due to participant overlap in two-sample Mendelian randomization. Genet. Epidemiol. 40, 597–608 (2016).
Chang, C. C. et al. Second-generation PLINK: rising to the challenge of larger and richer datasets. Gigascience 4, 7 (2015).
Auton, A. et al. A global reference for human genetic variation. Nature 526, 68–74 (2015).
Hemani, G. et al. The MR-Base platform supports systematic causal inference across the human phenome. Elife 7, e34408 (2018).
doi: 10.7554/eLife.34408
Candia, J. et al. Assessment of variability in the SOMAscan assay. Sci. Rep. 7, 14248 (2017).
SomaLogic. Short Technical Note. https://somalogic.com/wp-content/uploads/2019/07/Short-Technical-Note-SOMAmer-specificity.pdf (2019).
Centers for Disease Control and Prevention. Duration of isolation and precautions for adults with COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/hcp/duration-isolation.html (2021).
Cevik, M. et al. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. Lancet Microbe 2, e13–e22 (2020).